The Fetal Medicine Foundation

14th World Congress in Fetal Medicine

Crete 2015

DIAMOND SPONSOR

Why Choose HARMONY?

The Harmony Prenatal Test is a cell-free DNA based blood test which screens for trisomies 21 (Down syndrome), 18, and 13 from as early as 10 weeks of pregnancy.

VISIT BOOTH 1

- Unsurpassed accuracy for any age or risk
  - Blinded studies in over 22,000 women of all ages
  - Less than 0.1% false-positive rate for trisomy 21
- Most widely used test—in over 400,000 pregnancies and 100 countries
- Performed as early as 10 weeks
- May minimize invasive procedures caused by false-positive results

For further information regarding the benefits of the Harmony Prenatal Test, please contact us at **1-855-927-4672** or **+1 925-854-6246** outside the USA, or visit our website at **harmonytest.com**

harmony™
PRENATAL TEST

Ariosa DIAGNOSTICS

14th World Congress in Fetal Medicine

Sunday 21st June 2015 Joint session with the IFMSS

09:10 - 10:40	Fetal surgery for congenital diaphragmatic hernia
10:40 - 11:00	Pregnancy after uterine transplantation
11.30 - 13:30	Fetal surgery for open spina bifida
15:00 - 16:06	Fetal cardiac interventions
16:06 - 16:40	Fetal thoracic interventions
16:40 - 17:00	Chemotherapy in pregnancy
17:30 - 18:42	New therapies and imaging modalities
18:42 - 19:00	Neurosurgical planning and navigation
19:00 - 19:15	CMV: results of CYMBAL trial of valaciclovir
19:15 - 19:20	CMV: Pharmakokinetics of immunoglobulin therapy
19:20 - 19:40	Microbiome and pregnancy complications
19:40 - 20:00	The artificial placenta
21:00 - 24:00	Welcome party

Monday 22nd June 2015 Joint session with the IFMSS

08:00 - 09:00	Fetal echocardiography course
09:00 - 11:00	Complications of monochorionic twins
11:30 - 12:00	In utero cell therapy
12:00 - 20:00	Screening and diagnosis of chromosomal abnormalities

Tuesday 23rd June 2015

09:00 - 12:40	Impaired placentation - FGR
12:40 - 12:50	Functional imaging of the human placenta
12:50 - 13:05	Maternal gene therapy to improve fetal growth
16:00 - 18:40	Impaired placentation – PE
18:40 - 19:00	Gynecological scanning in pregnancy
21:00 - 03:00	Dinner party

Wednesday 24th June 2015

09:00 - 10:20	Gestational diabetes / fetal macrosomia
10:20 - 10:35	Prevalence of severe structural abnormalities today
10:35 - 10:48	A cryptic congenital anomaly
10:48 - 11:00	Diagnosis of fetal defects at 11-13 weeks
11:30 - 13:15	Fetal echocardiography
15.10 - 16:30	Neurosonography
18:00 - 20:00	Preterm birth

Thursday 25th June 2015

09:00 - 09:10	New FMF software for screening of PE
09:10 - 09:20	Biplan modalities to assist in invasive procedures
09:20 - 09:35	4D fetal echocardiography
09:35 - 09:43	Maternal mortality
09:43 - 09:50	Implications of fetal echogenic bowel
09:50 - 10:10	Labor and delivery
10:10 - 13:00	PRactical Obstetric Multi Professional Training
16:00 - 23:00	Trip to Knossos / Iraklion

DIAMOND SPONSOR

panorama™
natera prenatal screen

Identify DNA "Fingerprints" for Greater Accuracy

DID YOU KNOW THAT DNA FROM A VANISHED TWIN CAN LEAD TO INACCURATE RESULTS WITH SOME NON-INVASIVE PRENATAL SCREENING TESTS (NIPTS)?

The Panorama™ prenatal screen from Natera can distinguish between different DNA "fingerprints" in a sample of the mother's blood, such as those from vanishing twins. This leads to:

- **Reduced false positives**
- **Highly accurate fetal sex determination**

STOP BY THE NATERA BOOTH #3 for information on the Panorama™ NIPT, and details on the article recently published in the American Journal of Obstetrics and Gynecology.

natera™
Conceive. Deliver.

Panorama: part of the Natera family of products

panorama™ natera prenatal screen | horizon™ natera carrier screen | spectrum™ natera preimplantation genetics (PGS/PGD) | anora™ natera miscarriage test (POC)

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1-855-866-(6478) | Fax 1-650-730-2272

DIAMOND SPONSOR

CAN YOU DISTINGUISH BABY FROM MOM?

Panorama™ Can

Visit Natera at **Booth #3**

natera™
Conceive. Deliver.

Panorama: part of the Natera family of products

panorama™ natera prenatal screen | horizon™ natera carrier screen | spectrum™ natera preimplantation genetics (PGS/PGD) | anora™ natera miscarriage test (POC)

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1-855-866-(6478) | Fax 1-650-730-2272

Sunday 21st June 2015

08:00 - 09:00 Registration

Joint session with the International Fetal Medicine and Surgery Society

09:00 - 09:10	Welcome to the World Congress	Kypros Nicolaides (UK) Jan Deprest (Belgium)
09:10 - 10:40	**Fetal surgery for congenital diaphragmatic hernia (CDH)** Discussants: Alan Flake (USA), Eduard Gratacos (Spain)	
09:10 - 09:22	CDH: postnatal outcome	Francois Luks (USA)
09:22 - 09:34	CDH: prenatal management	Jan Deprest (Belgium)
09:34 - 09:42	CDH: TOTAL trial	Phillip DeKoninck (Australia)
09:42 - 09:50	CDH: prediction of outcome by ultrasound	Nicolas Sananes (USA)
09:50 - 09:58	CDH: meta-analysis for prediction of pulmonary hypertension	Francesca Russo (Italy)
09:58 - 10:06	FETO: 3 year experience	Isabella Fabietti (Italy)
10:06 - 10:14	CDH: MRI findings after FETO	Patrice Eastwood (UK)
10:14 - 10:22	CDH: whole transcriptome analysis after TO	Alexander Engels (Germany)
10:22 - 10:30	CDH: trans-placental sildenafil	Francesca Russo (Italy)
10:30 - 10:38	CDH: intra-tracheal VEGF	Stavros Loukogeorgakis (UK)
10:40 - 11:00	**Pregnancy after uterine transplantation**	Mats Brännström (Sweden)
11:00 - 11:30	**Coffee break**	
11.30 - 13:30	**Fetal surgery for open spina bifida (OSB)** Discussants: Martin Meuli (Switzerland), Mark Johnson (USA), Scott Adzick (USA)	
11:30 - 11:40	OSB: prenatal diagnosis by ultrasound	Rabih Chaoui (Germany)
11:40 - 11:55	OSB: prenatal assessment by MRI	Gregor Kasprian (Austria)
11:55 - 12:10	OSB: outcome after open fetal surgery	Scott Adzick (USA)
12:10 - 12:15	OSB: obstetrical outcome after open fetal surgery	Mark Johnson (USA)
12:15 - 12:20	OSB: technique for fetoscopic surgery	Yinka Olutoye (USA)
12:20 - 12:30	OSB: outcome after fetoscopic surgery	Denise Pedreira (Brazil)
12:30 - 12:35	OSB: outcome after mini-hysterotomy	Fabio Peralta (Brazil)
12:35 - 12:50	OSB: Debate on method of surgery	
12:50 - 12:58	How to match MOMS	Uhli Moehrlen (Switzerland)
12:58 - 13:06	Patient flow since introduction of OSB surgery	Tim Van Mieghem (Belgium)
13.06 - 13:30	**OSB: translational research**	
13:06 - 13:14	Cell spheroid based tissue engineering	Miho Watanabe (USA)
13:14 - 13:22	Umbilical cord-patch material for SB repair	Ramesh Pappana (USA)
13:22 - 13:30	Trans-amniotic stem cell therapy	Beatrice Dionigi (USA)
14:00 - 15:00	**Lunch break**	
15:00 - 16:06	**Fetal cardiac interventions** Discussants: Rabih Chaoui (Germany), Wolfgang Arzt (Austria)	
15:00 - 15:12	Prenatal diagnosis of aortic and pulmonary stenosis	Vita Zidere (UK)
15:12 - 15:25	MRI imaging of the heart	Kuberan Pushparajah (UK)
15:25 - 15:33	5, 4, 3, 2, 1: embryological variants of pentalogy of Cantrell	Bhavika Kaul (USA)
15:33 - 15:48	Fetal interventions for congenital cardiac malformations	Wolfgang Arzt (Austria)
15:48 - 15:53	Fetal cardiac surgery: experience from France	Julien Stirnemann (France)
15:53 - 15:58	Fetal cardiac surgery: experience from Poland	Marzena Debska (Poland)
15:58 - 16:06	Discussion	
16:06 - 16:40	**Fetal thoracic interventions** Discussants: Greg Ryan (Canada), Dick Oepkes (Netherlands)	
16:06 - 16:16	CPAM: open fetal surgery	Scott Adzick (USA)
16:16 - 16:24	CPAM: maternal corticosteroids	Mark Johnson (USA)
16:24 - 16:32	Shunting for hydrothorax: neonatal outcome	Ruben Witlox (Netherlands)
16:32 - 16:40	Thoracocentesis for severe hydrothorax	Venu Jain (Canada)
16:40 - 17:00	**Chemotherapy in pregnancy**	Frederic Amant (Belgium)
17:00 - 17:30	**Coffee break**	

Sunday 21st June 2015

Joint session with the International Fetal Medicine and Surgery Society

17:30 - 18:42	**New therapies and imaging modalities in fetal medicine** Discussants: Luc De Catte (Belgium), Gregor Kasprian (Austria)	
17:30 - 17:38	Gastroschisis: outcome after planned preterm delivery	Carmen Mesas Burgos (Sweden)
17:38 - 17:46	Gastroschisis: prenatal predictors of neonatal outcome	Roopali Donepudi (USA)
17:46 - 17:54	LUTO: outcome after cystoscopic ablation of PUVs	Nicolas Sananes (USA)
17:54 - 18:02	Fetal goiter size: sequential amniotic fluid thyroid hormone	Mark Evans (USA)
18:02 - 18:10	Lung texture analysis to predict neonatal respiratory morbidity	Eduard Gratacos (Spain)
18:10 - 18:18	3D image reconstruction in fetal surgery planning	Rosalind Pratt (UK)
18:18 - 18:26	MRI in assessment of Hct and SaO2 in fetal blood	Mark Osmond (Canada)
18:26 - 18:34	US and MRI for follow up after death of a twin	Anne-Maude Morency (Canada)
18:34 - 18:42	Mind the gap	Rabih Chaoui (Germany)
18:42 - 19:00	**Neurosurgical planning and navigation**	Sebastien Ourselin (UK)
19:00 - 19:15	**CMV: results of CYMBAL trial of valaciclovir**	Yves Ville (France)
19:15 - 19:20	**CMV: Pharmakokinetics of immunoglobulin therapy**	Oliver Kagan (Germany)
19:20 - 19:40	**Microbiome and pregnancy complications**	Elaine Holmes (UK)
19:40 - 20:00	**The artificial placenta**	Alan Flake (USA)
21:00 - 24:00	**Welcome party**	

PLATINUM SPONSOR

Empowering informed choices that can change lives.

Genomic solutions in reproductive and genetic health.

Illumina® is a trusted leader in innovative, accurate genomic technologies and now offers a comprehensive portfolio of genetic solutions to improve options in reproductive and genetic health.

From preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) to Non-invasive Prenatal Testing (NIPT), Cytogenetics, and Inherited Condition Screening, Illumina offers a range of solutions across the care continuum.

Learn more about how our industry-leading, next-generation sequencing (NGS) and microarray technologies deliver reliable, accurate information that can guide choices and transform lives.

Visit www.illumina.com/rgh to learn more.

illumina®

Monday 22nd June 2015

Joint session with the International Fetal Medicine and Surgery Society

08:00 - 09:00 **Fetal echocardiography course**
Presenters: Vita Zidere, Kuberan Pushparajah (UK)

08:00 - 08:40	Systemic and pulmonary vein abnormalities	
08:40 - 09:00	Asymmetry of the fetal heart	

09:00 - 11:00 **Complications of monochorionic twins**
Discussants: Kurt Hecher (Germany), Liesbeth Lewi (Belgium), Ken Moise (USA)

09:00 - 09:08	TTTS: prediction of neonatal morbidity	Yves Ville (France)
09:08 - 09:16	TTTS: nature of neonatal morbidity	Enrico Lopriore (Netherlands)
09:16 - 09:24	TTTS: impact of surgical techniques on prognosis	Julien Stirnemann (France)
09:24 - 09:32	TTTS: risk of donor death	Saul Snowise (USA)
09:32 - 09:40	TTTS: postoperative recurrent TTTS and TAPS	Roopali Donepudi (USA)
09:40 - 09:48	TTTS: laser surgery and fetal cardiac longitudinal motion	Fatima Crispi (Spain)
09:48 - 09:56	TTTS: recipient umbilical artery elongation	Roopali Donepudi (USA)
09:56 - 10:04	TTTS: neurodevelopment after laser surgery	Jeanine van Klink (Netherlands)
10:04 - 10:12	TTTS: impact of screening on staging at presentation	Julien Stirnemann (France)
10:12 - 10:20	TTTS: outcome after laser surgery in triplets	Asma Khalil (UK)
10:20 - 10:28	RFA: effect of starting power and fetal presentation	Mark Johnson (USA)
10:28 - 10:38	sFGR: expectant management	Liesbeth Lewi (Belgium)
10:38 - 10:48	sFGR: active management	Eduard Gratacos (Spain)
10:48 - 11:00	sFGR: debate	

11:00 - 11:30 **Coffee break**

11:30 - 12:00 **In utero cell therapy**
Discussants: Alan Flake (USA), Anna David (UK)

11:30 - 11:38	Enhanced engraftment of hematopoietic stem cells	Camila Fachin (USA)
11:38 - 11:46	Hematopoietic engraftment of amniotic fluid stem cells	Stavros Loukogeorgakis (UK)
11:46 - 11:54	Trans-amniotic stem cell therapy in gastroschisis	Christina Feng (USA)
11:54 - 12:02	Placental and umbilical cord blood stem cells in preeclampsia	Zahra Masoumi (Sweden)

12:00 - 20:00 **Screening and diagnosis of chromosomal abnormalities**
Discussants: Kypros Nicolaides (UK), Yves Ville (France), Howard Cuckle (Israel)

12:00 - 12:15	Overview	Kypros Nicolaides (UK)
12:15 - 12:25	The origin of the origin of Down syndrome	Eugene Pergament (USA)
12:25 - 12:35	Implications of fetoplacental mosaicism	Francesca Grati (Italy)
12:35 - 12:45	Price of abandoning invasive testing	Mark Evans (USA)
12:45 - 12:52	Pathogenic CNVs in the presence of US abnormalities	Richard Choy (China)
12:52 - 13:00	Inadequacy of cfDNA test in cases of increased fetal NT	Alexandra Benachi (France)
13:00 - 13:08	Replacing FTS by cfDNA test: remaining risk for aneuploidies	Oliver Kagan (Germany)
13:08 - 13:16	Expanded carrier screening	James Goldberg (USA)
13:16 - 13:30	Discussion	

14:00 - 15:00 **Lunch break**

Screening for trisomies 21, 18, 13

15:30 - 15:36	Combined test: implementation in Hong Kong	Daljit Sahota (China)
15:36 - 15:42	Combined test: implementation in Czechia	Pavel Calda (Czechia)
15:42 - 15:48	Combined test: profile of women refusing screening	Hanne Trap Wolf (Denmark)
15:48 - 15:54	cf DNA test: factors affecting uptake	Nerea Maiz (Spain)
15:54 - 16:00	cf DNA test: impact on CVS rate and indications	Stefan Kane (Australia)
16:00 - 16:10	Discussion	
16:10 - 16:18	cf DNA test: clinical validation of the IONA test	Brenda Kelly (UK)
16:18 - 16:22	cf DNA test: performance of the IONA test at 11-13 weeks	Liona Poon (UK)
16:22 - 16:30	cf DNA test: clinical validation of the Veracity test	George Koumbaris (Cyprus)
16:30 - 16:38	cf DNA test: clinical performance and counseling	Kirsten Curnow (USA)
16:38 - 16:45	cf DNA test: positive predictive value	Tak Yeung Leung (China)
16:45 - 17:00	Discussion	

17:00 - 17:30 **Coffee break**

Monday 22nd June 2015

17:30 - 20:00	**Screening and diagnosis of chromosomal abnormalities** Discussants: Kypros Nicolaides (UK), Yves Ville (France), Howard Cuckle (Israel)	
	cf DNA test: Management of failed result	
17:30 - 17:36	Factors affecting fetal fraction	Fabricio Costa (Australia)
17:36 - 17:40	Differences in estimates from different laboratories	Jacques Jani (Belgium)
17:40 - 17:46	Fetal-fraction based risk and redraw success	Allison Ryan (USA)
17:46 - 17:52	Low fetal fraction: results of samples after redraw	Thomas Musci (USA)
17:52 - 18:05	Discussion	
	cf DNA test: Clinical implementation	
18:05 - 18:15	NEXT study	Thomas Musci (USA)
18:15 - 18:25	UK NHS study	Mar Gil (UK)
18:25 - 18:30	Copenhagen study	Caroline Borregaard (Denmark)
18:30 - 18:35	Italian study	Nicola Persico (Italy)
18:35 - 18:40	cf DNA test: screening in twins	Jacques Jani (Belgium)
18:40 - 18:55	Discussion	
	cf DNA test: Screening for sex chromosome aneuploidies	
18:55 - 19:00	cf DNA test: results from the Danish study	Ann Tabor (Denmark)
19:00 - 19:10	Discussion	
	Screening by cf DNA for microdeletions	
19:10 - 19:20	Prevalence of pathogenic microdeletions / microduplications	Francesca Grati (Italy)
19:20 - 19:30	cf DNA test: screening for 22q11.2 deletion syndrome	Susan Gross (USA)
19:30 - 19:40	cf DNA test: screening for microdeletions / microduplications	Mathias Ehrich (USA)
19:40 - 19:50	cf DNA test: e karyotyping	Frederic Amar (Switzerland)
19:50 - 20:00	Discussion	

GOLD SPONSOR

HUMAN HEALTH
ENVIRONMENTAL HEALTH

PRE-ECLAMPSIA SCREENING FOR ALL TRIMESTERS

DELFIA® Xpress PℓGF 1-2-3

Pre-eclampsia screening in all three trimesters

- 1st trimester: Predict to prevent pre-eclampsia
- 2nd trimester: Reassess and monitor
- 3rd trimester: Aid in diagnosis

We look forward to seeing you at the PerkinElmer booth no. 5 in Olympus hall

www.perkinelmer.com/maternalfetalhealth

Product claims may differ from country to country based on regulations and product approvals. PerkinElmer products mentioned here are not available in the USA and Japan. Prior to registration, products are not available in China, Canada, certain Latin American countries and certain Asian countries. Please contact your country representative for further details.

PerkinElmer
For the Better

GOLD SPONSOR

the IONA® test

The first IVD product for non-invasive prenatal screening

A new advanced Non-Invasive Prenatal Test (NIPT) for Down's syndrome and other serious genetic conditions.

Allowing pregnant women fast, reliable results and reducing the need for invasive tests and the associated stress and anxiety.

The IONA® test is for pregnant women to estimate the probability that their fetus is affected with:

- Trisomy 21 (Down's syndrome)
- Trisomy 18 (Edwards' syndrome)
- Trisomy 13 (Patau's syndrome)

Please come and visit us at our booth at the 14th World Congress in Fetal Medicine

Key features of the IONA® test:

- CE-IVD NIPT which allows local screening for pregnant women
- Results available in 3-5 days
- Analyses cell-free fetal DNA from a sample of maternal blood
- >99% detection and <1% false positive rate
- Includes IONA® Software for analysis
- Generates easy to interpret results

For more information:
Email: **iona@premaitha.com**
Tel: **+44(0)161 667 6865**

www.premaitha.com

premaithahealth

Tuesday 23rd June 2015

09:00 - 12:40	**Impaired placentation - FGR** Discussants: Gerry Visser (Netherlands), Eduard Gratacos (Spain)	
09:00 - 09:15	Overview	Gerry Visser (Netherlands)
09:15 - 09:30	Implications of TRUFFLE study	Kurt Hecher (Germany)
09:30 - 09:45	Placental findings in impaired placentation	Neil Sebire (UK)
09:45 - 10:00	Placental vs non-placental late SGA	Eduard Gratacos (Spain)
10:00 - 10:15	FGR: does size matter?	Basky Thialaganathan (UK)
10:15 - 10:30	SGA: timing of 3rd trimester scan	Liona Poon (UK)
10:30 - 10:45	Prediction of adverse perinatal outcome	Ranjit Akolekar (UK)
10:45 - 11:00	Discussion	
11:00 - 11:30	**Coffee break**	
11:30 - 11:38	FGR: placental expression of PAPPA, PAPPA-2 and PLAC-1	Stavros Sifakis (Greece)
11:38 - 11:46	FGR: circulating and myometrial markers of oxidative stress	Ayse Kirbas (Turkey)
11:46 - 11:54	FGR: environmental enrichment and neurodevelopment	Miriam Illa (Spain)
11:54 - 12:02	FGR: effect of steroids on fetal circulation	Laura Marchi (Netherlands)
12:02 - 12:10	FGR: prediction by placental vascular biopsy	Cahit Birdir (Germany)
12:10 - 12:18	FGR: prediction by biomarkers in the 1st trimester	Francesca Crovetto (Spain)
12:18 - 12:26	Reproducibility of TV / TA 1st trimester uterine artery PI	Laura Marchi (Netherlands)
12:26 - 12:34	FGR: prediction by angiogenic factors in the 3rd trimester	Anthony Odibo (USA)
12:34 - 12:40	Discussion	
12:40 - 12:50	**Functional imaging of the human placenta**	Laurent Salomon (France)
12:50 - 13:05	**Maternal gene therapy to improve fetal growth**	Anna David (UK)
14:00 - 15:00	**Lunch break**	
16:00 - 18:40	**Impaired placentation – PE** Discussants: Gerry Visser (Netherlands), Kypros Nicolaides (UK)	
16:00 - 16:08	2nd trimester prediction of stillbirth	Alessandra Familiari (UK)
16:08 - 16:16	Reduced fetal movements at term	Carolina Scala (UK)
16:16 - 16:24	Perinatal loss in twins: fetal biometry and Doppler	Asma Khalil (UK)
16:24 - 16:40	Investigation of stillbirth	Neil Sebire (UK)
16:40 - 16:55	PE: not a placental disorder	Basky Thialaganathan (UK)
17:00 - 17:30	**Coffee break**	
17:30 - 17:38	PE: 1st trimester maternal immunological profile	Mauro Para-Cordero (Chile)
17:38 - 17:45	PE: prediction by sFlt-1 in the 2nd and 3rd trimesters	Dahiana Gallo (UK)
17:45 - 18:00	PE: competing risk model	David Wright (UK)
18:00 - 18:08	PE in twins: effect of chorionicity	Katrine Vasehus Schou (Denmark)
18:08 - 18:16	PE in twins: 1st trimester prediction	Ran Svirsky (Israel)
18:16 - 18:24	PE in twins: prediction by sFlt-1 / PlGF	Jesus Rodriguez Calvo (Spain)
18:24 - 18:32	Prevention of PE / FGR: impact of aspirin dose	Stephanie Roberge (Canada)
18:32 - 18:40	Prevention of PE: RCT of aspirin 80 vs 160 mg	Emmanuel Bujold (Canada)
18:40 - 19:00	**Gynecological scanning in pregnancy**	Dimitris Mavrelos (UK)
21:00 - 03:00	**Dinner party**	

SILVER SPONSOR

Understanding Pregnancy Care

Complete solution from early gestation until delivery

Broad Elecsys® menu for pregnancy testing

- Preeclampsia
- Down Syndrome screening
- TORCH group infections
- Thyroid hormones
- Other tests for pregnant women (infectious diseases, Vitamin D, anemia, …)

Proven clinical and technical performance for a better maternal and fetal care.

Roche

cobas® *Life needs answers*

SILVER SPONSOR

sequenom Laboratories

REVOLUTIONIZING PRENATAL CARE

NONINVASIVE PRENATAL TESTING OPTIONS FOR ALL

Noninvasive prenatal testing (NIPT) was pioneered by Sequenom Laboratories in 2011, and since then, several hundred thousand pregnant women worldwide have benefited. Many have avoided potentially unnecessary invasive procedures while still gaining important information about the health of their pregnancies.

Stop by our booth to learn more about the MaterniT21® PLUS and VisibiliT™ laboratory-developed tests, and to see what's next.

Sequenom Laboratories is proud to be a Silver Sponsor of the Fetal Medicine Foundation Meeting, June 21-25, 2015.

MaterniT GENOME
Coming in 2015

MaterniT21 PLUS
Clearly advanced.

VisibiliT
Simply relevant.

Email: info@sequenom.com Web: www.sequenom.com/laboratories

Wednesday 24th June 2015

09:00 - 10:20	**Gestational diabetes / fetal macrosomia** Discussants: Gerry Visser (Netherlands), John Hyett (Australia)	
09:00 - 09:12	Lifestyle intervention in obese pregnancies	Eugene Oteng (UK)
09:12 - 09:20	Vaginal birth: BW and adverse outcome	Eran Ashwal (Israel)
09:20 - 09:28	Amniotic fluid metabolic variations by NMRomics	Apostolos Athanasiadis (Greece)
09:28 - 09:43	Metformin for treatment of diabetes and metabolic syndrome	Hassan Shehata (UK)
09:43 - 09:55	1st trimester prediction of GDM	John Hyett (Australia)
09:55 - 10:07	Obesity in pregnancy: RCT of metformin treatment	Argyro Syngelaki (UK)
10:07 - 10:20	Challenges in GDM	Gerry Visser (Netherlands)
10:20 - 10:35	**Prevalence of severe structural abnormalities today**	Howard Cuckle (Israel)
10:35 - 10:48	**A cryptic congenital anomaly**	Reuven Achiron (Israel)
10:48 - 11:00	**Diagnosis of fetal defects at 11-13 weeks**	
10:48 - 10:54	Detection of non-chromosomal defects	Jesus Rodriguez Calvo (Spain)
10:54 - 11:00	Always detectable 9 and much more	Prathima Radhakrishnan (India)
11:00 - 11:30	**Coffee break**	
11:30 - 13:15	**Fetal echocardiography** Discussants: Rabih Chaoui (Germany), Vita Zidere (UK)	
11:30 - 11:45	First trimester diagnosis of heart defects	Rabih Chaoui (Germany)
11:45 - 12:00	Fetal vascular imaging	Reuven Achiron (Israel)
12:00 - 12:10	Prenatal disease and cardiovascular remodelling	Fatima Crispi (Spain)
12:10 - 12:16	Complete AVSD at 11-13 w: abnormal flow in DV and TV	Georgios Rembouskos (Italy)
12:16 - 12:22	Ductus venosus agenesis: diagnosis and outcome	Brunella Muto (Italy)
12:22 - 12:28	3VTV in screening for heart defects at 11-13 w	Valentina De Robertis (Italy)
12:28 - 12:34	ARSA: association with trisomy 21	Mar Bennasar (Spain)
12:34 - 12:40	ARSA: association with aneuploidies	Angela Ranzini (Belgium)
12:40 - 12:46	Right aortic arch: association with 22q11.2 deletion	Nicola Volpe (Italy)
12:46 - 12:52	Truncus versus pulmonary atresia with intact septum	Mar Bennasar (Spain)
12:52 - 12:58	Impact of prenatal diagnosis on mortality from d-TGA	Jesus Rodriguez Calvo (Spain)
12:58 - 13:04	Prenatal detection of coarctation of the aorta	Hedwig vd Nieuwenhof (Netherlands)
13:04 - 13:12	New technologies	Jader Cruz (Portugal)
14:00 - 15:00	**Lunch break**	
15.10 - 16:30	**Neurosonography** Discussants Rabih Chaoui (Germany), Katia Bilardo (Netherlands)	
15:10 - 15:25	Overview	Rabih Chaoui (Germany)
15:25 - 15:33	Abnormal posterior brain at 11 - 13 w	Tiziana Fanelli (Italy)
15:33 - 15:41	Virtual autopsy of the early fetal brain	Claudio Lombardi (Italy)
15:41 - 15:49	Corpus callosum in fetuses with heart defects	Carlos Montefusco Pereira (Spain)
15:49 - 15:57	Conus medullaris in spina bifida	Denise Pugash (Canada)
15:57 - 16:05	Isolated mild ventriculomegaly	Elisenda Eixarch (Spain)
16:05 - 16:13	Guideline on acquisition of brain volumes	Nerea Maiz (Spain)
16:13 - 16:21	CNS defects: evaluation by MRI and US fusion imaging	Bart De Keersmaecker (Belgium)
16:21 - 16:29	CNS defects: diagnosis in the third-trimester	Eldad Katorza (Israel)
17:00 - 17:30	**Coffee break**	
18:00 - 20:00	**Preterm birth** Discussants: Zarko Alfirevic (UK), Kypros Nicolaides (UK)	
18:00 - 18:20	Overview on strategies for prediction and prevention	Zarko Alfirevic (UK)
18:20 - 18:30	Discussion	
18:30 - 18:40	Tocolytics and corticosteroids	Gerry Visser (Netherlands)
18:40 - 18:50	Threatened PTB: PECEP-RETARD Trial	Elena Carreras (Spain)
18:50 - 18:57	Cervical cerclage in twins	Edwin Guzman (USA)
18:57 - 19:04	Short cervix : effect of long-term indomethacin	Ozhan Turan (USA)
19:04 - 19:11	PTB: prediction by circulating RNA markers	Stephen Chim (China)
19:11 - 19:18	PTB: prediction by mid trimester cervical length	Athena Souka (Greece)
19:18 - 19:25	PTB: cervical microbiome signature	Meng Meng (China)
19:25 - 19:32	PTB: amniotic fluid pro-inflammatory biomarkers	Emmanuel Bujold (Canada)
19:32 - 19:40	PPROM in twins: interval to delivery	Mark Osmond (Canada)
19:40 - 20:00	Discussion	

BRONZE SPONSOR

STANDARD SPONSORS

TOSHIBA
Leading Innovation

Counsyl

mindray
healthcare within reach

BGI

Thursday 25th June 2015

09:00 - 09:10	**New FMF software for screening of PE**	Kypros Nicolaides (UK)
09:10 - 09:20	**Biplan modalities to assist in invasive procedures**	Yves Ville (France)
09:20 - 09:35	**4D fetal echocardiography**	Rabih Chaoui (Germany)
09:35 - 09:43	**Maternal mortality**	Yaprak Engin-Üstün (Turkey)
09:43 - 09:50	**Implications of fetal echogenic bowel**	Mireille Bekker (Netherlands)
09:50 - 10:10	**Labor and delivery** Discussants: Gerry Visser (Netherlands), John Hyett (Australia)	
09:50 - 09:56	ECV for breech at term	Breffini Anglim (Ireland)
09:56 - 10:02	Prediction of time to delivery: elastography and Bishop Score	Krzysztof Preis (Poland)
10:02 - 10:08	Prediction of success of labor induction: fetal adrenal gland	Ozhan Turan (USA)
10:10 - 13:00	**PRactical Obstetric Multi Professional Training (PROMPT)** Moderator: Carl Weiner (USA)	
10:10 - 10:15	Introduction	Carl Weiner (USA)
10:15 - 10:30	Why PROMPT	Dimitrios Siassakos (UK)
10:30 - 10:45	PROMPT is exportable to high and low resource countries	Carl Weiner (USA)
10:45 - 11:00	Maternal collapse	Neil Muchatuta (UK)
11:00 - 11:30	**Coffee break**	
11:30 - 11:45	Shoulder dystocia	Carl Weiner (USA)
11:45 - 12:00	Maternal hemorrhage	Dimitrios Siassakos (UK)
12:00 - 12:15	Hypertensive emergencies	Neil Muchatuta (UK)
12:15 - 12:30	Maternal sepsis	Christine Burden (UK)
12:30 - 13:00	Structuring local training and simulation scenarios / Questions	Michelle Schulz (USA)
14:00 - 15:00	**Lunch break**	
16:00 - 23:00	**Trip to Knossos / Iraklion**	

The Fetal Medicine Foundation

Advances in Fetal Medicine Course
5 – 6 December 2015
London

Registration will open in August 2015
Limited Number of places

Registration fee is £150, which includes lunches and coffees

Speakers:

Reuven Achiron (Israel)
Scott Adzick (USA)
Ranjit Akolekar (UK)
Zarko Alfirevic (UK)
Frederic Amant (Belgium)
Frederic Amar (Switzerland)
Breffini Anglim (Ireland)
Wolfgang Arzt (Austria)
Eran Ashwal (Israel)
Apostolos Athanasiadis (Greece)
Mireille Bekker (Netherlands)
Alexandra Benachi (France)
Mar Bennasar (Spain)
Cahit Birdir (Germany)
Caroline Borregaard (Denmark)
Mats Brännström (Sweden)
Emmanuel Bujold (Canada)
Christine Burden (UK)
Pavel Calda (Czechia)
Elena Carreras (Spain)
Rabih Chaoui (Germany)
Stephen Chim (China)
Richard Choy (China)
Fabricio Costa (Australia)
Fatima Crispi (Spain)
Francesca Crovetto (Spain)
Jader Cruz (Portugal)
Howard Cuckle (Israel)
Kirsten Curnow (USA)
Anna David (UK)
Bart De Keersmaecker (Belgium)
Valentina De Robertis (Italy)
Marzena Debska (Poland)
Phillip DeKoninck (Australia)
Jan Deprest (Belgium)
Beatrice Dionigi (USA)
Roopali Donepudi (USA)
Patrice Eastwood (UK)
Mathias Ehrich (USA)
Elisenda Eixarch (Spain)
Alexander Engels (Germany)
Yaprak Engin-Üstün (Turkey)
Mark Evans (USA)
Isabelle Fabietti (Italy)
Camila Fachin (USA)
Alessandra Familiari (UK)
Tiziana Fanelli (Italy)
Christina Feng (USA)
Alan Flake (USA)
Dahiana Gallo (UK)
Mar Gil (UK)
James Goldberg (USA)
Eduard Gratacos (Spain)
Francesca Grati (Italy)
Susan Gross (USA)
Edwin Guzman (USA)
Kurt Hecher (Germany)
Elaine Holmes (UK)
John Hyett (Australia)
Miriam Illa (Spain)
Venu Jain (Canada)
Jacques Jani (Belgium)
Mark Johnson (USA)
Oliver Kagan (Germany)
Stefan Kane (Australia)
Gregor Kasprian (Austria)
Eldad Katorza (Israel)
Bhavika Kaul (USA)
Brenda Kelly (UK)
Asma Khalil (UK)
Ayse Kirbas (Turkey)
George Koumbaris (Cyprus)
Tak Yeung Leung (China)
Liesbeth Lewi (Belgium)
Claudio Lombardi (Italy)
Enrico Lopriore (Netherlands)
Stavros Loukogeorgakis (UK)
Francois Luks (USA)
Nerea Maiz (Spain)
Laura Marchi (Netherlands)
Zahra Masoumi (Sweden)
Dimitris Mavrelos (UK)
Meng Meng (China)
Carmen Mesas Burgos (Sweden)
Uhli Moehrlen (Switzerland)
Carlos Montefusco Pereira (Spain)
Anne-Maude Morency (Canada)
Neil Muchatuta (UK)
Thomas Musci (USA)
Brunella Muto (Italy)
Kypros Nicolaides (UK)
Anthony Odibo (USA)
Yinka Olutoye (USA)
Mark Osmond (Canada)
Eugene Oteng (UK)
Sebastien Ourselin (UK)
Ramesh Pappana (USA)
Mauro Para-Cordero (Chile)
Denise Pedreira (Brazil)
Fabio Peralta (Brazil)
Eugene Pergament (USA)
Nicola Persico (Italy)
Liona Poon (UK)
Rosalind Pratt (UK)
Krzysztof Preis (Poland)
Denise Pugash (Canada)
Kuberan Pushparajah (UK)
Prathima Radhakrishnan (India)
Angela Ranzini (Belgium)
Georgios Rembouskos (Italy)
Stephanie Roberge (Canada)
Jesus Rodriguez Calvo (Spain)
Francesca Russo (Italy)
Allison Ryan (USA)
Daljit Sahota (China)
Laurent Salomon (France)
Nicolas Sananes (USA)
Carolina Scala (UK)
Michelle Schulz (USA)
Neil Sebire (UK)
Hassan Shehata (UK)
Dimitrios Siassakos (UK)
Stavros Sifakis (Greece)
Saul Snowise (USA)
Athena Souka (Greece)
Julien Stirnemann (France)
Ran Svirsky (Israel)
Argyro Syngelaki (UK)
Ann Tabor (Denmark)
Basky Thialaganathan (UK)
Hanne Trap Wolf (Denmark)
Ozhan Turan (USA)
Jeanine van Klink (Netherlands)
Tim Van Mieghem (Belgium)
Katrine Vasehus Schou (Denmark)
Hedwig vd Nieuwenhof (Netherlands)
Yves Ville (France)
Gerry Visser (Netherlands)
Nicola Volpe (Italy)
Miho Watanabe (USA)
Carl Weiner (USA)
Ruben Witlox (Netherlands)
David Wright (UK)
Vita Zidere (UK)

The Fetal Medicine Foundation
UK Charity Number 1037116
137 Harley Street, London, W1G 6BG, UK
Tel: +44 (0) 207 034 3070
www.fetalmedicine.com